Piper Sandler analyst Yasmeen Rahimi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $4 from $17 and keeps an Overweight rating on the shares. The firm cites cash per share as there is uncertainty regarding the path forward in oncology. Piper notes that at Pliant’s Q2 update, management reiterated that bexotegrast development in IPF has been discontinued following a full analysis of safety/efficacy from Phase 2b/3 BEACON-IPF with full results to be submitted for a future publication.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX: